CS Medica and our product philosophy
Altogether, CS MEDICA currently focuses on a total of 20 products:
Six MD-based treatment products – the current Psoriasis and Arthritis Gel together with products introduced after H1 2020/2021; pain patches, wound care, Nasal Spray Night, and protective nasal gel.
Completed MD product introductions with ongoing sales:
- Psoriasis Gel.
- Arthritis Gel.
- Nasal Spray Night.
- Protective nasal gel.
- Wound gel.
- Pain patch.
Seven cosmetic CBD products – the current Anti-Hair Loss Serum and Psor Lotion with six pending products within the skincare line.
Completed cosmetic CBD product introductions with ongoing sales:
- Anti- Hair Loss serum.
Remaining cosmetic CBD product introductions:
- Psoriasis lotion.
- Repair and calm body milk.
- Deep clean and calm facial cleanser.
- Deep moisturizing cream.
- Recovery and calm cream.
- Repair lip balm.
Four pending products within food supplements (without CBD); arthritis-, psoriasis-, hair loss – and immune booster capsules.
Pending food supplements products:
- Hair regrowth capsules
- Psoriasis capsules
- Arthritis capsules
- Immune booster capsules
Three (four in total, with the previously counted Protective nasal gel) current; hand disinfection (without CBD – only in DK), surface disinfection (without CBD – only in DK), antibacterial hand cream (without CBD), and a protective nasal gel.
Completed COVID-19 protective product introductions with ongoing sales:
- Hand disinfection (without CBD – only in DK)
- Surface disinfection (without CBD – only in DK)
- Antibacterial hand cream (without CBD)
In total currently, eleven products are introduced with ongoing sales and nine of the 20 products are pending – being in the later stage of being launched on the European market during the period H1 2021/2022 and H1 2022/2023.
In 2022/2023, the Company expects to extend the current product line with product lines within;
- Animal treatment.
- CBD inhaler treatment (under the pharmaceutical legislation as medicine).